  |
| CuraGen Corporation |
| A systems biology approach to target identification and validation for human chronic disease drug discovery and development |
| Center for Drug Evaluation and Research, Food and Drug Administration |
| The Role of Pharmacogenetics/ Pharmacogenomics in Drug Development and Regulatory Review |
| Yale University School of Public Health |
| A systems biology approach to target identification and validation for human chronic disease drug discovery and development |
|
Array-On GmbH |
| Large-scale detection of genetic variation - the key to peronalised medicine | |
| Pharmaceuticals Division, F. Hoffmann-La Roche Ltd. | |
| The development of Herceptin®: Paving the way to individualized cancer therapy |
|
Avontec GmbH |
| Double stranded decoy oligonucleotide as new biopharmaceuticals | |
| Free University, Institut für Chemie/Biochemie | |
| Non-protein-coding RNAs and their potential as biopharmaceuticals | |
| Polish Academy of Science | |
| Non-protein-coding RNAs and their potential as biopharmaceuticals | |
| Mologen AG & Free University | |
| MIDGE vectors and dSLIM immunomodulators: DNA-based molecules for gene therapeutic strategies |
| Berlex Inc. | |
| Adenovirus-based Gene Therapy: Therapeutic Angiogenesis with Adenovirus 5 Fibroblast Growth Factor-4 (Ad5FGF-4) in Patients with Chronic Myocardial Ischemia |
|
Dharmacon, Inc. |
| Rational siRNA design for RNA interference: Optimization for therapeutic use and current applications | |
| University of Colorado | |
| Beginning to understand the end of the chromosome |
|
| College of Veterinary Medicine, Seoul National University |
| The first cloned human embryo: an unlimitated source of stem cells for therapeutic cloning |
|
| Columbia Presbyterian, Medical Center |
| Repair of infarcted myocardium by genetically enhanced mesenchymal stem cells |
|
Schering AG |
| Spheramine: a cell therapeutic approach against Parkinson disease |
|
| Sohnis Family Research Laboratory for the Regeneration of Functional Myocardium and the Rappaport Family Institute for Research in the Medical Sciences, The Bruce Rappaport Faculty of Medicine, Technion- Israel Institute of Technology |
| Myocardinal Regeneration Strategies Using Human Embryonic Stem Cells |
| Weizmann Institute of Science |
| Applying human cells for organogenesis and transplantation - how to create an artificial kidney |
|
Baxter AG |
| A new technology standart for safety and efficacy in FVIII replacement therapy: Designing the advanced category rFVIII concentrate ADVATE® | |
| Goethe-University of Frankfurt (Biocenter) | |
| Mechanism of serine proteinase activation: insights for the development of biopharmaceuticals for coagulation and fibrinolysis | |
| Max-Planck-Institut für Biochemie | |
| Application of the Principle of Polyvalency for Protease Inhibition |
|
Baxter Healthcare Corporation |
| A new technology standart for safety and efficacy in FVIII replacement therapy: Designing the advanced category rFVIII concentrate ADVATE® |
|
University of Jaén |
| AIDS gene therapy: A vector able to selectively destroy latently HIV-1 infected cells |
|
Beckman Research Institute of the City of Hope National Medical Center |
| Combinatorial RNA Based Therapies for the treatment of HIV infection |
|
Medical Enzymes AG |
| New directions in tumor therapy - amino acid depletion |
|
Leslie Dan Faculty of Pharmacy, University of Toronto |
| Biomolecules as targeting vehicles for in situ radiotherapy of malignancies |
| National Cancer Institute | |
| Nature's role in developing potent biopharmaceuticals |
|
DIREVO Biotech AG |
| Design of modern biopharmaceuticals by ultra-high throughput screening and directed evolution |
|
| Proteomics R&D, Invitrogen Corp. |
| Learning from Viruses: High throughput cloning using Gateway® to transfer genes without restriction enzymes |
|
Institut für Pharmazeutische Biologie, Universität Frankfurt/Main (Biozentrum) |
| An NIH model organism for biopharmaceutical research: the lower eukaryote Dictyostelium discoideum | |
| Max-Planck-Institut für Biochemie | |
| Knock-out mice as disease models and to discover true physiological gene functions | |
| University of Leiden | |
| Target validation an important early step in the development of novel biopharmaceuticals in the postgenomic era | |
| Goethe-University of Frankfurt (Biocenter) | |
| An NIH model organism for biopharmaceutical research: the lower eukaryote Dictyostelium discoideum |
|
Roche Diagnostics GmbH, Roche Applied Science |
| Accelerating Diagnostic Product Development Preocess with Molecular Irrational Design and Directed Evolution |
|
Crucell Holland N.V. |
| PER.C6: Development of a high yielding human cell line for production of biopharmaceuticals | |
| ProBioGen AG | |
| Humanized mouse cell line: human glycosylation combined with high protein expression | |
| Lausanne (EPFL) | |
| Manufacture of recombinant biopharmaceutical proteins by cultivated mammalian cells in bioreactors |
| Lonza Biologics plc | |
| Use of the glutamine synthetase (GS) expression system for the rapid development of highly productive mammalian cell processes |
| Europe / India: |
| Icon Genetics |
| Production of recombinant proteins in plants |
| Schering AG |
| Production of recombinant proteins in plants |
| CEO of Icon Genetics AG & Prof. at Academy of Sciences of Ukraine |
| Production of recombinant proteins in plants |
| Fraunhofer Institute for Molecular Biology and Applied Ecology (IME) |
| Biopharmaceutical production in cultured plant cells |
| greenovation Biotechnologie GmbH |
| Humanised glycosylation - production of biopharmaceuticals in a moss bioreactor |
| University of York |
| Biopharmaceutical production in cultured plant cells |
| The Bruce Rappaport Faculty of Medicine, Technion- Israel Institute of Technology |
| Producing biopharmaceuticals in the desert: Building an abiotic stress tolerance in plants for salt, heat ans drought |
| University of Delhi South Campus |
| Producing biopharmaceuticals in the desert: Building an abiotic stress tolerance in plants for salt, heat ans drought |
| USA: |
| FibroGen Inc. |
| Transgenic expression of Biopharmaceuticals in plants and animals |
| GTC Biotherapeutics Inc. |
| The first biopharmaceutical from transgenic animals: ATryn® - antithrombin III from goat milk |
| Ventria Bioscience |
| Trenagenic expression of Biopharmaceuticals in seeds |
| Berlex Inc. |
| Production of recombinant proteins in plants |
| University of California |
| Producing biopharmaceuticals in the desert: Building an abiotic stress tolerance in plants for salt, heat ans drought |
|
| Bayer HealthCare AG Pharma |
| Preparing for success - the Bayer experience with a broad range of expression systems |
| Novo Nordisk A/S |
| Advanced Expression of Biopharmaceuticals in Yeast at Industrial Scale: the Insulin Success Story |
| Swiss Federal Institute of Technology Zurich |
| Insectsell-based expression systems: boosting product yields while reducing time and costs |
| St. Vincent’s Institute of Medical Research |
| Robust, cost-effective and highly efficient cell-free expression of niopharmaceuticals: E. coli and wheat embryos |
|
|
Chemgineering AG |
| Contract Manufacturing of biopharmaceuticals |
|
AMGEN Switzerland AG |
| 30 Years of Monoclonal Antibodies: A long way to Pharmaceutical and Commercial Success | |
| Max-Planck-Institut für Biochemie | |
| Molecular Characterisation of Autoantibody Responses in Autoimmune Disseases - Implications for Diagnosis and Understanding of Autoimmunity | |
| MorphoSys AG | |
| Modern Antibody Technology: The Impact on Drug Development | |
| Sartorius AG - Biotechnology | |
| 30 Years of Monoclonal Antibodies: A long way to Pharmaceutical and Commercial Success |
|
Hammersmith Hospital |
| Design and Development of probes for in vivo molecular and functional imaging of cancer and cancer therapies by positron emission tomography (PET) | |
| Schering AG | |
| Ultrasound Theranostics: Antibody-based microbubble conjugates as targeted in vivo contrast agents and drug delivery system | |
| Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology Zurich (ETHZ) | |
| Ligand-based in vivo targeting of disease: from antibodies to small organic (synthetic) ligands | |
| Julius-Maximilians-University of Würzburg | |
| Ultrasound Theranostics: Antibody-based microbubble conjugates as targeted in vivo contrast agents and drug delivery system | |
| Orsel Philips Research | |
| Molecular Imaging and Applications for Drug Discovery |
|
| ISAS - Institute for Analytical Sciences |
| Early detection og lung cancer: metabolic profiling of human breath with ion mobility spectrometers |
| Ciphergen Biosystems |
| Development of multi-marker based diagnostic assays with the ProteinChip® System |
|
Schering AG |
| Advanced Drug Delivery Systems for Biopharmaceuticals |
|
Intercell AG |
| Novel adjuvants based on cationic drug delivery systems: a therapeutic vaccine against Hepatitis C |
| Kyoto Pharmaceutical University | |
| Improvement of transmucosal absorption of peptide and protein drugs |
| Generex Biotechnology Corp. |
| The Evolving Role of Oralin® (oral spray insulin) in the Treatment of Diabetes using a Novel RapidMist™ Diabetes Management System |
|
|
Nektar Therapeutics |
| Poly(ethylene) Glycol Conjugates of Biopharmaceuticals in Drug Delivery |
| Graduate School of Pharmaceutical Sciences, Hokkaido University, Kita 12, Nishi 6 | |
| "Programmed Packaging" - A New Drug Delivery System and ist Application to Gene Therapy | |
| Kyoto University | |
| Liposomal in vivo gene delivery |
|
AP Pharma |
| DNA Delivery from Poly(Ortho Ester) Microspheres | |
| Massachusetts Institute of Technology | |
| DNA Delivery from Poly(Ortho Ester) Microspheres |
|
University of Groningen |
| BioNanotechnology and its role to improve biopharmaceuticals |
|
Schering AG |
| Analytics in quality control and in vivo |
|
Center for Drug Evaluation and Research, Food and Drug Administration |
| Regulatory aspects of approvin Biopharmaceuticals in the US - the FDA perspective |
|
PSST Pharma Scientific Services Team |
| The Regulatory Environment for Biopharmaceuticals in the EU |
| Astex Technology Ltd. | |
| Crystal structures of drug-metabolising human cytochrome P450s |
|
| Business Development, Amura Therapeutics Ltd., Incenta House | |
| Mettox™: A Suite of Predictive in Silicon and in Vitro Assays for Metabolic and Genotoxicological Profiling of Preclinical Drug Candidates |
|
McKinsay & Company |
| Health-care trends and their impact on the biopharmaceutical industry |
|
mondoBIOTECH Group |
| Science meets business: Innovative biopharmaceuticals for rare and yet unattended diseases |
|
McKinsey & Company |
| Health-care trends and their impact on the biopharmaceutical industry |
|
Dragon Pharmaceuticals Inc. |
| Biogenerics and the emergence of healthcare economics: G-CSF and bioequivalence |
|
Stanford University |
| Engineering and Overproduction of Polyketide Natural Products |
|
Charité Campus Benjamin Franklin |
| Bioinformatics - from peptides to profiled compounds: Pep2Lead and Prediction of ASMETox Properties |
| Headquarter: Berlin |  |
| Dr. Knäblein | |
| Munich | |
| Professor Huber, Max-Planck-Institute for Biochemistry |
| Melbourne | |
| Professor Caruso |
| Korea | |
| Professor Hwang, Seoul National University |
|
| San Francisco |
| Professor McCaman |
| Massachusetts |
| Professor Langer, MIT |
| New York |
| Professor Watson, Cold Spring Harbor Laboratory |
| Colorado |
| Professor Cech, Howard Hughes Medical Institute |
| Singapore | |
| Professor Ullrich, Biopolis |
|
Moscow |
| Professor Gleba, Academy of Sciences |
| Taiwan | |
| Professor Spielberger, Taipeh Hospital |